SearchMedica.com receives award
FDA has approved expanded labeling for single-agent Campath (alemtuzumab) as a first-line treatment of B-cell chronic lymphocytic leukemia.SearchMedica.com, the specialty oriented professional medical search engine, has received the 2007 Health Care Standard of Excellence WebAward from the Web Marketing Association.
NEW YORKSearchMedica.com, the specialty oriented professional medical search engine, has received the 2007 Health Care Standard of Excellence WebAward from the Web Marketing Association. The Standard of Excellence is awarded for outstanding achievement in website innovation, design, and ease of use.
"Doctors tell us that SearchMedica is much more effective and efficient than consumer search engines," said Cyndy Finnie, senior product manager for SearchMedica. "Receiving this honor shows that the greater online community is taking notice."
SearchMedica Oncology is more comprehensive than PubMed, more selective than Google, and is designed to save time by displaying search results by categories of information, the company said in a press release. To try SearchMedica, visit www.searchmedica.com/oncology.
MammoScreen AI Tool Improves Diagnostic Performance of Radiologists in Detecting Breast Cancer
December 16th 2020This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Preliminary Results Suggest AB-MR Detects Breast Cancers that 3-D Mammograms May Miss
November 29th 2020This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.
DeepSurv Displays Possible Benefits in Prognostic Evaluation, Treatment Recommendation
July 20th 2020The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.
